Phage Therapy in the 21st Century: Is There Modern, Clinical Evidence of Phage-Mediated Efficacy?
Phage Therapy in the 21st Century: Is There Modern, Clinical Evidence of Phage-Mediated Efficacy?
复制标题
DOI：
10.3390/ph14111157
复制
发表时间：
2021-11-13
期刊：
影响因子：
--
通讯作者：
Alves DR
中科院分区：
文献类型：
--
作者：
Abedon ST;Danis-Wlodarczyk KM;Alves DR
许多噬菌体是细菌的专职杀手。这一特性在一百多年前就被首次认识到了，2021年是第一个临床噬菌体疗法发表100周年。在这里，我们考虑噬菌体在临床环境中的现代使用。我们的目的是回答一个问题：在临床使用时，噬菌体是否可以作为有效的抗细菌感染剂？我们分析的一个重要重点是，是否可以合理地区分噬菌体疗法相关的抗细菌感染效果与经常联合使用抗生素的效果。我们发现，到目前为止，在本世纪头十年以英文发表的70份人类噬菌体治疗报告中，约有一半暗示了噬菌体介导的抗细菌感染效果。其中两项是随机、双盲的感染治疗研究，而在我们看来，其中14项研究提供了噬菌体在观察到的治疗成功中所起作用的更好的证据。在这些潜在的噬菌体介导的结果中，大约四分之三是基于微生物学和临床结果，其余的基于临床成功。由于这些噬菌体疗法中的许多都是抗生素治疗不成功的感染，它们的集体有效性表明，利用噬菌体治疗原本难以治愈的细菌感染是有效的。
Many bacteriophages are obligate killers of bacteria. That this property could be medically useful was first recognized over one hundred years ago, with 2021 being the 100-year anniversary of the first clinical phage therapy publication. Here we consider modern use of phages in clinical settings. Our aim is to answer one question: do phages serve as effective anti-bacterial infection agents when used clinically? An important emphasis of our analyses is on whether phage therapy-associated anti-bacterial infection efficacy can be reasonably distinguished from that associated with often coadministered antibiotics. We find that about half of 70 human phage treatment reports—published in English thus far in the 2000s—are suggestive of phage-mediated anti-bacterial infection efficacy. Two of these are randomized, double-blinded, infection-treatment studies while 14 of those studies, in our opinion, provide superior evidence of a phage role in observed treatment successes. Roughly three-quarters of these potentially phage-mediated outcomes are based on microbiological as well as clinical results, with the rest based on clinical success. Since many of these phage treatments are of infections for which antibiotic therapy had not been successful, their collective effectiveness is suggestive of a valid utility in employing phages to treat otherwise difficult-to-cure bacterial infections.
登录
查看更多内容
DOI：
10.3390/antibiotics10020124
发表时间：
2021-01-28
期刊：
Antibiotics (Basel, Switzerland)
影响因子：
--
作者：
Abdelrahman F;Easwaran M;Daramola OI;Ragab S;Lynch S;Oduselu TJ;Khan FM;Ayobami A;Adnan F;Torrents E;Sanmukh S;El-Shibiny A
通讯作者：
El-Shibiny A
影响因子：
11.8
作者：
Corbellino, Mario;Kieffer, Nicolas;Poirel, Laurent
通讯作者：
Poirel, Laurent
基于Endolysin的工程“ Artilysins”来对抗耐多药的革兰氏阴性病原体。
影响因子：
6.4
作者：
Briers Y;Walmagh M;Van Puyenbroeck V;Cornelissen A;Cenens W;Aertsen A;Oliveira H;Azeredo J;Verween G;Pirnay JP;Miller S;Volckaert G;Lavigne R
通讯作者：
Lavigne R
影响因子：
4.6
作者：
Blasco, Lucia;Ambroa, Anton;Tomas, Maria
通讯作者：
Tomas, Maria
DOI：
10.1080/21597081.2015.1020260
发表时间：
2015-01
期刊：
Bacteriophage
影响因子：
--
作者：
Abedon ST
通讯作者：
Abedon ST